Altshuler Shaham Ltd Sells 35,149 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Altshuler Shaham Ltd trimmed its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 22.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 124,681 shares of the company’s stock after selling 35,149 shares during the period. Altshuler Shaham Ltd’s holdings in Teva Pharmaceutical Industries were worth $1,311,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Desjardins Global Asset Management Inc. increased its holdings in Teva Pharmaceutical Industries by 15.2% in the 4th quarter. Desjardins Global Asset Management Inc. now owns 8,123 shares of the company’s stock worth $85,000 after buying an additional 1,070 shares during the period. DekaBank Deutsche Girozentrale grew its holdings in shares of Teva Pharmaceutical Industries by 2.1% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 67,996 shares of the company’s stock worth $688,000 after purchasing an additional 1,375 shares during the period. ClariVest Asset Management LLC increased its position in shares of Teva Pharmaceutical Industries by 0.4% during the third quarter. ClariVest Asset Management LLC now owns 399,900 shares of the company’s stock valued at $4,079,000 after acquiring an additional 1,400 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in Teva Pharmaceutical Industries by 0.8% in the third quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 178,827 shares of the company’s stock valued at $1,824,000 after purchasing an additional 1,500 shares during the period. Finally, Transcend Capital Advisors LLC lifted its stake in Teva Pharmaceutical Industries by 13.6% during the 4th quarter. Transcend Capital Advisors LLC now owns 12,543 shares of the company’s stock worth $131,000 after acquiring an additional 1,500 shares in the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have commented on TEVA shares. Piper Sandler upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and increased their price target for the company from $12.00 to $19.00 in a research note on Monday, February 12th. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 target price for the company in a report on Friday, March 8th. Jefferies Financial Group upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and raised their price target for the company from $10.00 to $14.00 in a research report on Tuesday, January 23rd. The Goldman Sachs Group upped their target price on Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the company a “neutral” rating in a research note on Monday, February 5th. Finally, StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 1st. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $14.11.

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA traded up $0.27 during trading hours on Thursday, reaching $16.01. The company had a trading volume of 16,779,394 shares, compared to its average volume of 10,858,707. The stock has a 50-day moving average of $13.70 and a two-hundred day moving average of $11.72. The firm has a market capitalization of $17.95 billion, a PE ratio of -34.06, a PEG ratio of 1.67 and a beta of 1.04. Teva Pharmaceutical Industries Limited has a one year low of $7.09 and a one year high of $16.25. The company has a quick ratio of 0.69, a current ratio of 1.02 and a debt-to-equity ratio of 2.23.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Mark Sabag sold 100,000 shares of the company’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the sale, the executive vice president now directly owns 382,590 shares of the company’s stock, valued at $5,172,616.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, VP Eric Drape sold 9,815 shares of the company’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $13.12, for a total transaction of $128,772.80. Following the completion of the sale, the vice president now directly owns 9,701 shares in the company, valued at approximately $127,277.12. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Mark Sabag sold 100,000 shares of the stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the completion of the sale, the executive vice president now owns 382,590 shares of the company’s stock, valued at approximately $5,172,616.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 358,972 shares of company stock valued at $4,739,820. Company insiders own 0.55% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.